Last reviewed · How we verify

NCT05781425: NFL-BIOPAIN

Prediction of Getting Peripheral Neuropathy in Patients Treated With Bortezomib?

Completed Last updated 31 July 2025
What this trial tests

trial in Chemotherapy-induced Peripheral Neuropathy in 20 participants. Completed in 29 July 2025.

Timeline
12 May 2023
Primary endpoint
24 April 2025
29 July 2025

Quick facts

Lead sponsorOdense University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment20
Start date12 May 2023
Primary completion24 April 2025
Estimated completion29 July 2025
Sites2 locations across Denmark

Conditions studied

Sponsor

Odense University Hospital

Who can join

18 and older, any sex, with Chemotherapy-induced Peripheral Neuropathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Investigation of which patients treated with bortezomib that have increased risk of developing peripheral neuropathy.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chemotherapy-induced Peripheral Neuropathy

Currently open trials in the same condition.

Other Odense University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05781425.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing